.avif)
Mirati Therapeutics Email Format
Biotechnology Research
・
201-500 employees
・
San Diego, CA, USA
Mirati Therapeutics is a biotechnology company focused on developing breakthrough therapies that target the genetic drivers of cancer, now part of Bristol Myers Squibb.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
firstinitiallast@mirati.com
Company Overview
Industry
Biotechnology Research
Founded
2013
Headquarters
San Diego, CA, USA
Revenue
$10M-$25M
FUNDING Stage
Acquired
Website
Key Executives
Charles M. Baum (President, Chief Executive Officer and Founder)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Mirati Therapeutics?
Mirati Therapeutics uses the firstinitiallast format, so Jane Smith would be jsmith@mirati.com.
What cancer types does Mirati Therapeutics target with its KRAZATI therapy?
Mirati Therapeutics developed KRAZATI (adagrasib), which has received FDA accelerated approval for adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer and, in combination with cetuximab, for KRAS G12C-mutated metastatic colorectal cancer.
When did Bristol Myers Squibb complete its acquisition of Mirati Therapeutics?
Bristol Myers Squibb completed its acquisition of Mirati Therapeutics on January 23, 2024, in an all-cash deal valued at approximately 4.8 billion dollars. Mirati Therapeutics now operates as a subsidiary of Bristol Myers Squibb, continuing its oncology work from San Diego, CA.
How can I find and verify contact details for Mirati Therapeutics employees?
Since Mirati Therapeutics uses the firstinitiallast format at mirati.com, you can construct a likely address for any employee. Tools like Clay can help you verify those addresses and enrich your prospect list with additional contact data for the Mirati Therapeutics team.
Where is Mirati Therapeutics headquartered and what is its primary scientific focus?
Mirati Therapeutics is headquartered at 3545 Cray Court in San Diego, California, and its primary scientific focus is targeted oncology, particularly the discovery and development of therapies that inhibit KRAS mutations driving cancer growth.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating